Amino acid compositions and methods for the treatment of liver diseases
AssigneeAxcella Health Inc.
InventorsMichael Hamill, Raffi Afeyan, Chung-Wei Lee, Harry Luithardt, David Berry
Life of this patent
Estimating the term…
Abstract
This disclosure provides pharmaceutical compositions comprising amino acid entities and uses thereof. Methods for improving liver function and for treating liver diseases comprising administering an effective amount of the compositions to a subject in need thereof are also disclosed.
Claims20
A method for treating liver dysfunction or liver disease in a human, wherein the method comprises administering to a human subject in need thereof an effective amount of a composition comprising:
- (a) a leucine amino acid entity chosen from:
- (i) L-leucine or a salt thereof,
- (ii) a dipeptide or salt thereof, or tripeptide or salt thereof, comprising L-leucine, or
- (iii) β-hydroxy-β-methylbutyrate (HMB) or a salt thereof;
- (b) an arginine amino acid entity chosen from:
- (i) L-arginine or a salt thereof,
- (ii) a dipeptide or salt thereof, or tripeptide or salt thereof, comprising L-arginine,
- (iii) ornithine or a salt thereof,
- (iv) a dipeptide or salt thereof, or tripeptide or salt thereof, comprising ornithine,
- (v) creatine or a salt thereof, or
- (vi) a dipeptide or salt thereof, or tripeptide or salt thereof, comprising creatine;
- (c) L-glutamine or a salt thereof or a dipeptide or salt thereof, or tripeptide or salt thereof, comprising L-glutamine;
- and
- (d) N-acetylcysteine (NAC) or a salt thereof or a dipeptide or salt thereof, or tripeptide or salt thereof, comprising NAC,
- wherein when the composition is in powder form at least 50 wt. % of the total wt. of the composition is one or more amino acid entities in free form, and wherein the total wt. % of (a)-(d) is greater than the total wt. % of other amino acid entities in the composition.
A method for treating a fatty liver disease, wherein the method comprises administering to a human subject in need thereof an effective amount of a composition comprising:
- (a) a leucine amino acid entity chosen from:
- (i) L-leucine or a salt thereof,
- (ii) a dipeptide or salt thereof, or tripeptide or salt thereof, comprising L-leucine, or
- (iii) β-hydroxy-β-methylbutyrate (HMB) or a salt thereof;
- (b) an arginine amino acid entity chosen from:
- (i) L-arginine or a salt thereof,
- (ii) a dipeptide or salt thereof, or tripeptide or salt thereof, comprising L-arginine,
- (iii) ornithine or a salt thereof,
- (iv) a dipeptide or salt thereof, or tripeptide or salt thereof, comprising ornithine,
- (v) creatine or a salt thereof, or
- (vi) a dipeptide or salt thereof, or tripeptide or salt thereof, comprising creatine;
- (c) L-glutamine or a salt thereof or a dipeptide or salt thereof, or tripeptide or salt thereof, comprising L-glutamine;
- and
- (d) N-acetylcysteine (NAC) or a salt thereof or a dipeptide or salt thereof, or tripeptide or salt thereof, comprising NAC,
- wherein when the composition is in powder form at least 50 wt. % of the total wt. of the composition is one or more amino acid entities in free form, and wherein the total wt. % of (a)-(d) is greater than the total wt. % of other amino acid entities in the composition.
A method for treating liver dysfunction or liver disease in a human, wherein the method comprises administering to a human subject in need thereof an effective amount of a pharmaceutical composition consisting essentially of:
- (a) L-leucine or a salt thereof;
- (b) L-arginine or a salt thereof;
- (c) L-glutamine or a salt thereof;
- (d) N-acetylcysteine (NAC) or a salt thereof;
- (e) L-isoleucine or a salt thereof;
- (f) L-valine or a salt thereof;
- and
- (g) one or more pharmaceutically acceptable excipients.
Dependencies are inferred from the claim text.